Access cutting-edge immune thrombocytopenia treatment through this clinical trial at a research site in New Haven. Study-provided care at no cost to qualified participants.
Access immune thrombocytopenia specialists in New Haven at no cost
This study follows strict safety protocols and ethical guidelines
All study-related immune thrombocytopenia treatment provided free
The main purpose of this study is to look at the effect (efficacy) and safety of efgartigimod IV in participants with primary immune thrombocytopenia (ITP). After an up to 2 weeks screening period, eligible participants will be randomized in a 2:1 ratio to receive either efgartigimod IV or placebo IV, respectively during the double-blinded treatment period (DBTP). At the end of the treatment period (up to 24 weeks), all participants will receive efgartigimod IV during the first 52-week open-labe
Sponsor: argenx
Check if you qualify for this immune thrombocytopenia clinical trial in New Haven, CT
If you're searching for immune thrombocytopenia treatment options in New Haven, CT, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our New Haven research site is actively enrolling participants for this clinical trial. You'll receive care from experienced immune thrombocytopenia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.